- Home
- SYBX vs BCLI Comparison
SYBX vs BCLI Comparison
Compare SYBX & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- BCLI
- Stock Information
- Founded
- SYBX N/A
- BCLI 2000
- Country
- SYBX United States
- BCLI United States
- Employees
- SYBX N/A
- BCLI N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYBX Health Care
- BCLI Health Care
- Exchange
- SYBX Nasdaq
- BCLI Nasdaq
- Market Cap
- SYBX 16.5M
- BCLI 13.5M
- IPO Year
- SYBX N/A
- BCLI N/A
- Fundamental
- Price
- SYBX $1.43
- BCLI $2.13
- Analyst Decision
- SYBX Hold
- BCLI Strong Buy
- Analyst Count
- SYBX 3
- BCLI 1
- Target Price
- SYBX $1.00
- BCLI $30.00
- AVG Volume (30 Days)
- SYBX 24.4K
- BCLI 83.9K
- Earning Date
- SYBX 03-18-2025
- BCLI 11-14-2024
- Dividend Yield
- SYBX N/A
- BCLI N/A
- EPS Growth
- SYBX N/A
- BCLI N/A
- EPS
- SYBX N/A
- BCLI N/A
- Revenue
- SYBX $2,777,000.00
- BCLI N/A
- Revenue This Year
- SYBX N/A
- BCLI N/A
- Revenue Next Year
- SYBX N/A
- BCLI N/A
- P/E Ratio
- SYBX N/A
- BCLI N/A
- Revenue Growth
- SYBX 292.23
- BCLI N/A
- 52 Week Low
- SYBX $1.22
- BCLI $1.05
- 52 Week High
- SYBX $3.73
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- SYBX 49.27
- BCLI 52.92
- Support Level
- SYBX $1.36
- BCLI $1.86
- Resistance Level
- SYBX $1.47
- BCLI $2.33
- Average True Range (ATR)
- SYBX 0.08
- BCLI 0.18
- MACD
- SYBX 0.00
- BCLI -0.02
- Stochastic Oscillator
- SYBX 43.75
- BCLI 51.92
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.